AbbVie (ABBV) Common Equity (2012 - 2026)

AbbVie (ABBV) has reported Common Equity for 15 consecutive years, with -$5.9 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 4200.72% year-over-year to -$5.9 billion in Q2 2026; TTM through Jun 2026 was -$5.9 billion, a 4200.72% decrease from a year earlier, with the FY2025 full-year figure at -$3.3 billion, down 197.21% from the prior year.
• Common Equity was -$5.9 billion for Q2 2026 at AbbVie, up from -$6.6 billion in the prior quarter.
• Over five years, Common Equity peaked at $17.3 billion in Q4 2022 and troughed at -$6.6 billion in Q1 2026.
• A 5-year average of $6.7 billion and a median of $7.4 billion in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity rose 18.79% in 2022 and plunged 4200.72% in 2026, its largest moves.
• Over 5 years, Common Equity stood at $17.3 billion in 2022, then plunged by 39.86% to $10.4 billion in 2023, then sank by 67.64% to $3.4 billion in 2024, then plunged by 197.21% to -$3.3 billion in 2025, then sank by 81.5% to -$5.9 billion in 2026.
• The last three Common Equity figures came in at -$5.9 billion (Q2 2026), -$6.6 billion (Q1 2026), and -$3.3 billion (Q4 2025), per Business Quant data.